Literature DB >> 8449835

Treatment of intra-abdominal infections.

S L Gorbach1.   

Abstract

Intra-abdominal infections are caused by a mixture of aerobic, anaerobic and facultatively anaerobic bacteria. Experimental studies in animals and clinical trials indicate that antimicrobial therapy should provide adequate coverage for the whole range of isolates. Penicillins and cephalosporins with relatively limited activity against anaerobes have been associated with clinical failures in treating various types of mixed infections. Aminoglycosides are often used in combination with other drugs in the treatment of intra-abdominal infections. Recent studies have cast doubt on this practice because of increased resistance of Gram-negative bacilli to aminoglycosides and high rates of renal toxicity. Regimens that do not include an aminoglycoside have given good results in treatment of appendicitis, penetrating abdominal trauma, and peritonitis. Enterococci are frequently isolated from intra-abdominal infections, but evidence suggests that it is not necessary to direct treatment at this organism initially.

Entities:  

Mesh:

Year:  1993        PMID: 8449835     DOI: 10.1093/jac/31.suppl_a.67

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

2.  Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.

Authors:  D J Walters; J S Solomkin; J A Paladino
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

3.  Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group.

Authors:  H Dupont; C Carbon; J Carlet
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

4.  Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Authors:  C Jaccard; N Troillet; S Harbarth; G Zanetti; D Aymon; R Schneider; R Chiolero; B Ricou; J Romand; O Huber; P Ambrosetti; G Praz; D Lew; J Bille; M P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 5.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.